InoLife Technologies, Inc. Announces Immediate Availability of the Cytochrome P450 2C1 Plavix Metabolizing Test to the …

RALEIGH, NC–(Marketwire – September 8, 2010) – InoLife Technologies, Inc. ( OTCBB : INOL ), a service based healthcare products development, integration and marketing Company, is extremely pleased that their recently presented Cytochrome P450 2C1 test to determine a person’s ability to metabolize Plavix is immediately available to the medical industry which includes physicians, hospitals …